Abbott launches leukaemia-related DNA tests in Europe

Abbott Molecular has this week announced the introduction in Europe of six CE-marked DNA tests for the identification of chromosomal abnormalities. The abnormalities detected by the tests are associated with some forms of leukaemia.

The tests are founded on the company’s fluorescence in situ hybridisation technology (Fish) that uses DNA probes for the detection of extra or reorganised chromosomes or other abnormalities that are often found in patients with a variety of forms of leukaemia.

Abbott reports that these new tests are designed to be used in conjunction with standard cytogenetic testing to provide additional information regarding specific chromosome defects.

Timothy Stenzel, medical director of Abbott Molecular, said: “Certain generic aberrations can be important indicators of whether a patient has a particularly aggressive form of leukaemia or whether they will respond to certain therapy.”

He added that the new technology can help doctors make specific diagnoses between different forms of leukaemia that may have similar symptoms but differing genetic abnormalities. The identification of these diverse aberrations may result in the administration of different treatments to patients.

Also this week, Abbott announced that the Federal Trade Commission in the US has agreed to the early finish of the waiting period relating to the company’s acquisition of Kos Pharmaceuticals, with other standard conditions now needing to be met before the purchase is completed.